The Daily Byte
Breaking
Welcome to The Daily Byte — real stories from across Pakistan.
Saturday, 21 November 2026 · Pakistan

The Daily Byte

Stories from Pakistan that deserve to be heard
Minor UK News

Cancer Pill ERAS-0015 Shrinks Pancreatic Tumours in Trial

By The Daily Byte ·21 Nov 2026 ·3 min read
A scientist in a lab coat and blue gloves examining pill blister packs beside a microscope in a laboratory

An experimental daily pill shrank tumours in many patients with advanced pancreatic and lung cancers in an early-stage trial, researchers reported on Friday, in results that offer fresh hope against two of the hardest cancers to treat.

The drug, ERAS-0015, is being developed by the US biotech company Erasca. Updated results from its first human trial, AURORAS-1, were presented on Friday at the EORTC-NCI-AACR cancer symposium in Barcelona, and the company announced the findings the same day.

ERAS-0015 is a so-called molecular glue drug designed to block faulty RAS proteins, which act as on-off switches for cell growth but can get stuck in the “on” position when they mutate, driving the uncontrolled growth behind many common and deadly cancers. The trial enrolled people whose cancers carry RAS mutations and who had already been through standard treatment.

The pancreatic cancer results

In pancreatic cancer, 25 patients taking a 32 mg daily dose of the drug after previous chemotherapy saw their tumours shrink significantly in 44% of cases, Erasca said. The patients were heavily pre-treated: 84% were receiving the drug as a third-line treatment or later, meaning they had already tried at least two earlier courses of therapy.

In patients with the two most common genetic variations of the disease, known as KRAS G12D and G12V, the response rate rose to 69%. Those two variations account for nearly 70% of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer.

The analysis covered 148 trial participants with RAS gene alterations, including 83 people with pancreatic cancer and 37 with non-small cell lung cancer. Over a median follow-up of just over four months, the maximum tolerated dose had not yet been reached, and enrolment in the trial continues.

Lung cancer and other tumours

In lung cancer, 60% of five patients who had already received immunotherapy and chemotherapy responded to the drug at the same 32 mg dose. The company also reported a 58% response rate across the 16 mg to 32 mg dose range in second- and third-line lung cancer, and a 75% response rate in patients with biliary tract cancer at the 32 mg dose.

The treatment was generally well tolerated, Erasca said, with mostly low-grade side effects and low rates of dose interruptions, reductions and discontinuations. The company had earlier reported one death from lung inflammation in a patient taking a 24 mg dose of the drug.

ERAS-0015 is being tested as a single treatment and in combination with other cancer drugs. Early combination data with chemotherapy and with the immunotherapy drug pembrolizumab support testing it as part of combination treatment, the company said.

What happens next

Erasca said it plans to start a potentially registration-enabling trial in second-line or later lung cancer in the first half of 2027, and a phase 3 trial in first-line lung cancer in the second half of 2027. It is also accelerating the planned start of a phase 3 trial in first-line pancreatic cancer to the first half of 2027, and expects to begin testing ERAS-0015 alongside a second experimental treatment, ERAS-4001, in 2027.

The results are early and the numbers in some groups are small, particularly the five lung cancer patients at the 32 mg dose, so longer follow-up is needed before anyone can say how durable the responses will be. The drug is not an approved treatment, and patients should not seek it outside a clinical trial.

The findings were presented at the same Barcelona symposium as results for a different pancreatic cancer pill, daraxonrasib, which is made by another company and was tested in combination with chemotherapy. The two drugs are separate treatments and their results should not be mixed up.

Source: Reuters
Source: Erasca
Source: MedPath